Brief: Asit Biotech Announces Results From Phase III Trial Of gp-ASIT+ Treatment

European Medical Solutions SA

25/11/2019 06:19

Nov 25 (Reuters) - Asit Biotech SA  ASIT.BR :
    * ASIT BIOTECH GP-ASIT+™ PHASE III TRIAL IN GRASS POLLEN
ALLERGY
DID NOT MEET PRIMARY ENDPOINT
    * STUDY RESULTS SHOWED 0.15 (P=0.05) ABSOLUTE REDUCTION IN
CSMS,
DURING PEAK OF GP SEASON, AND 0.18 (P=0.005) ABSOLUTE REDUCTION
IN CSMS DURING ENTIRE GP SEASON, TRANSLATING INTO TREATMENT
EFFECT OF 7.4% AND 9.8% RESPECTIVELY VERSUS. 20% EXPECTED
    * ALTHOUGH THE CONDUCT OF THE STUDY WAS FLAWLESS AND DESPITE
A
GOOD SAFETY PROFILE CONSISTENT WITH PREVIOUS RESULTS, THESE
EFFICACY RESULTS ARE DISAPPOINTING - CEO
    * WE WILL ANALYZE DATA FURTHER AND ASSESS BEST OPTIONS FOR
COMPANY
ON WHICH WE WILL COMMUNICATE BY YEAR END -CEO
    * 24 NOV 2019 CASH POSITION EUR 3.8 MILLION
    * PHASE III TRIAL OF GP-ASIT+(™), HAS RANDOMIZED 650
PATIENTS FROM
BELGIUM, CZECH REPUBLIC, FRANCE, GERMANY, HUNGARY AND POLAND

Source text for Eikon:  ID:nBwbGz77Fa 
Further company coverage:  ASIT.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))